Home
Drugs
Leucovorin
Clinical Trials

Clinical Trials Related to Leucovorin

Related studies linked through entity extraction aliases.

A Study to Evaluate Efficacy and Safety of Tislelizumab Plus Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma in Racial and Ethnic Minority Patients in the United States

Status: RECRUITING
Phase: PHASE2

A Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor Cancer

Status: RECRUITING
Phase: PHASE1

A Phase II Study of AMT-676 Combination Therapies in Advanced Colorectal Cancer

Status: NOT_YET_RECRUITING
Phase: PHASE2

Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)

Status: RECRUITING
Phase: PHASE2

Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

Status: RECRUITING
Phase: PHASE3

A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies

Status: RECRUITING
Phase: PHASE2

A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer

Status: RECRUITING
Phase: PHASE3

A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors

Status: RECRUITING
Phase: PHASE1

AACR Adaptive Biomarker-Driven Organ Preservation Trial in Gastroesophageal Adenocarcinomas

Status: NOT_YET_RECRUITING
Phase: PHASE2

A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tumors

Status: RECRUITING
Phase: PHASE1

Hypofractionated Radiotherapy Combined With NALIRIF, PD-1 Antibody in Locally Recurrent Rectal Cancer(NOVELTY-R)

Status: RECRUITING
Phase: PHASE2

Utility of ctDNA in Early Switch of First-line mFOLFIRINOX in Metastatic Pancreatic Ductal Adenocarcinoma

Status: RECRUITING
Phase: PHASE2

Evaluating NALIRIFOX vs Modified Gemcitabine, Nab-Paclitaxel and Cisplatin in Patients With Locally Advanced and Metastatic Pancreatic Adenocarcinoma

Status: RECRUITING
Phase: PHASE2

Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEA

Status: RECRUITING
Phase: PHASE2

A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Status: RECRUITING
Phase: PHASE3

PANORAMIX : Optimizing 1st-line NALIRIFOX and Exploring Microbiota's Role in 2nd Line Pancreatic Cancer Treatment

Status: NOT_YET_RECRUITING
Phase: PHASE2

A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer

Status: RECRUITING
Phase: PHASE1

Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations

Status: RECRUITING
Phase: PHASE3

A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer

Status: RECRUITING
Phase: PHASE2

Gemcitabine Plus Nab-paclitaxel as Switch Maintenance Versus Continuation of Modified FOLFIRINOX as 1st Line Chemotherapy in Patients With Advanced Pancreatic Cancer.

Status: RECRUITING
Phase: PHASE3